EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of AL cardiac amyloidosis with intravenous high-dose melphalan and stem cell transplantation



Treatment of AL cardiac amyloidosis with intravenous high-dose melphalan and stem cell transplantation



Journal of the American College of Cardiology 39(5 Supplement A): 136A, March 6




(PDF same-day service: $19.90)

Accession: 035980317

Download citation: RISBibTeXText

DOI: 10.1016/s0735-1097(02)80596-4



Related references

High dose intravenous melphalan and autologous stem cell transplantation for the treatment of AL amyloidosis Morbidity and mortality. Blood 98(11 Part 1): 860a, November 16, 2001

Five years experience with high dose intravenous melphalan and autologous peripheral blood stem cell transplantation for the treatment of patients with AL Amyloidosis. Blood 94(10 SUPPL 1 PART 1): 396a, Nov 15, 1999

High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney International 63(3): 1051-1057, 2003

An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid 14(4): 261-269, 2007

High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood 119(5): 1117-1122, 2012

Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood 108(12): 3945-3947, 2006

Treatment of AL amyloidosis with tandem cycles of high dose melphalan and autologous stem cell transplantation. Blood 102(11): 117-118a, November 16, 2003

Cardiac transplant followed by high-dose melphalan and autologous stem cell transplantation (ASCT) for patients with AL amyloidosis and severe heart failure. 2007

Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation. Clinical and Experimental Nephrology 13(5): 522-525, 2009

High dose melphalan and autologous stem cell transplantation after VAD chemotherapy for treatment of systemic light chain amyloidosis. Blood 98(11 Part 2): 397b, November 16, 2001

Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis. Annals of Hematology 89(6): 579-584, 2010

Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation 90(8): 905-911, 2010

Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis. Transplant Infectious Disease 15(2): 187-194, 2013

Treatment of AL amyloidosis patients with high dose melphalan and autologous stem cell transplantation produces durable remissions and improvement in quality of life. Blood 102(11): 452a-453a, November 16, 2003

Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease. Annals of Internal Medicine 134(9 Pt 1): 746-753, 2001